Quick answers
- What is Myxredlin?
- Myxredlin is a brand name of Insulin human, a prescription medicine. The FDA NDC Directory lists 1 Myxredlin product in 1 strength and form.
- Who makes Myxredlin?
- Baxter Hlthcare Corp holds the FDA application for Myxredlin (BLA208157, approved June 20, 2019).
- Is there a generic or store brand of Myxredlin?
- Other products of Insulin human are listed with the FDA, but none in exactly the same strength and form as a Myxredlin product.
- Has Myxredlin been recalled?
- FDA enforcement reports list 1 recall of Myxredlin products; the newest started August 6, 2026. A recall usually concerns specific lots, not every product.
What Myxredlin is
Each Myxredlin product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Insulin human · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| insulin human 1 units/mL injection, solution (intravenous) | Myxredlin | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Insulin human →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA208157 | Baxter Hlthcare Corp | June 20, 2019 | 1 |
Companies that list Myxredlin
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Myxredlin products.
- Baxter Healthcare Corporation1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
August 6, 2026 · Class II · Ongoing · D-0806-2026
CGMP Deviations
MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12. — Baxter Healthcare Corporation
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.